Preparation method of roxadustat and its intermediates

By using a method for preparing nitro compounds and mild reaction conditions, the problems of genetic impurities and high costs in the synthesis of roxadustat were solved, resulting in high yield and improved safety.

CN118164864BActive Publication Date: 2026-11-17北京海美源医药科技有限公司
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202410284013.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-13
Publication Date
2026-11-17
Estimated Expiration
2044-03-13

AI Technical Summary

Technical Problem

Existing methods for synthesizing roxadustat use nitro compounds, which lead to genetic impurities; precious metals, which result in high costs; and harsh reaction conditions, which result in low yields.

Method used

The preparation method of non-nitrate compounds is adopted, which uses an organic or inorganic base to react with an amination reagent in an alkaline environment, avoids precious metals, controls the reaction temperature at 0-25℃, and the time is 1-1.5 hours.

Benefits of technology

This improved the safety and yield of roxadustat intermediates, reduced production costs, and simplified reaction conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118164864B_ABST
    Figure CN118164864B_ABST
Patent Text Reader

Abstract

This invention relates to the field of compound synthesis technology, and more specifically, to a method for preparing roxadustat and its intermediates. The synthesis is carried out according to the following synthetic route, wherein R1 is selected from C1-C6 alkyl groups. This preparation method avoids the use of nitro compounds, thus avoiding the introduction of genetic impurities and improving drug safety. It also avoids the use of precious metals, significantly reducing production costs. Furthermore, this preparation method features mild reaction conditions, short reaction time, and greatly improved yield.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of compound synthesis technology, and more specifically, to a method for preparing roxadustat and its intermediates. Background Technology

[0002] Roxadustat belongs to the 4-hydroxyisoquinoline derivative class and is a small-molecule HIF-PH enzyme inhibitor. HIF is an important transcription factor for adapting to changes in oxygen levels in the body. Under normal oxygen conditions, HIF-PH enzyme promotes HIF degradation; when the body is hypoxic, the activity of HIF-PH enzyme is inhibited, leading to increased HIF accumulation, which in turn induces the expression of corresponding genes, enabling the body to adapt to hypoxia. Roxadustat stabilizes HIF, inhibits its degradation, activates the transcription of related genes, and produces corresponding physiological responses. It moderately increases the concentration of erythropoietin, enhances the sensitivity of erythropoietin (EChemicalbookPO) receptors, coordinates erythrocyte production, reduces hepcidin levels, increases the content and activity of transferrin receptors, promotes iron absorption and utilization, and is well tolerated.

[0003] In existing technologies, roxadustat is generally synthesized through organic synthesis, and there are multiple synthetic routes. Among them, the compound shown in Formula III below is an important intermediate in the synthesis of roxadustat.

[0004] Patent CN111499572A also discloses the synthesis of this compound, but it uses nitro compounds, leading to genetic impurities in the roxadustat intermediate and even roxadustat itself, which can easily reduce drug safety. Furthermore, this patent uses precious metals such as Pd, significantly increasing the synthesis cost of roxadustat. In addition, the reaction conditions in this patent are harsh, the reaction time is long, and the yield from the starting materials to the intermediate shown in Formula III is low.

[0005] In view of this, the present invention is proposed. Summary of the Invention

[0006] The purpose of this invention is to provide a method for preparing roxadustat and its intermediates. The preparation method provided in this invention avoids the use of nitro compounds, thus preventing the introduction of genetic impurities and improving drug safety. It also avoids the use of precious metals, significantly reducing production costs. Furthermore, this preparation method features mild reaction conditions, short reaction time, and a greatly improved yield.

[0007] This invention is implemented as follows:

[0008] In a first aspect, the present invention provides a method for preparing a roxadustat intermediate, which is synthesized according to the following synthetic route:

[0009] R1 is selected from C1-C6 alkyl groups.

[0010] In an optional embodiment, R1 is selected from C1-C5 alkyl groups;

[0011] Preferably, R1 is selected from C1-C4 alkyl groups;

[0012] More preferably, R1 is selected from C1-C3 alkyl groups; more preferably, it is methyl or ethyl.

[0013] In an optional embodiment, the reaction includes: mixing the compound of Formula I with an amination reagent under an alkaline environment;

[0014] Preferably, the reaction involves mixing the compound of Formula I, the solvent, and the amination reagent under an alkaline environment.

[0015] In an optional embodiment, the alkaline substance forming the alkaline environment is selected from organic or inorganic bases; preferably, it is any one of hydroxides, carbonates, bicarbonates, sodium C1-C6 alkoxides and potassium C1-C6 alkoxides; preferably, it is any one of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide and sodium n-propoxide.

[0016] In an optional embodiment, the amination agent is selected from hydroxylamine reagents;

[0017] More preferably, H2N-O-R2, Hydroxylaminophosphate, diphenylphosphonohydroxylamine, O-(trimethylsilyl)hydroxylamine, wherein R2 is selected from C1-C6 alkyl or C3-C6 cycloalkyl; R3 is selected from any one of hydroxyl, -OR4 and substituted or unsubstituted aryl, wherein R4 is selected from C1-C6 alkyl or C3-C6 cycloalkyl;

[0018] Preferably, R3 is selected from hydroxyl, -OR4, C6-C10 aryl, and more preferably R3 is selected from any one of hydroxyl, -OR4, phenyl and benzyl;

[0019] Preferably, the amination reagent is selected from...

[0020] In an optional embodiment, the solvent is selected from protic solvents or aprotic solvents; preferably, the protic solvent is selected from water, C1-C5 alcohol solvents, and more preferably any one of water, methanol, ethanol and propanol;

[0021] Preferably, the aprotic solvent is selected from furan solvents, C1-C3 chloroalkyl solvents, aromatic solvents, and oxygen-substituted C3-C6 rings;

[0022] More preferably, the aprotic solvent is selected from any one of toluene, tetrahydrofuran, dichloromethane, and dioxane.

[0023] In an optional embodiment, the molar ratio of the compound of Formula I to the alkaline substance is 0.5:(0.3-1.5).

[0024] In an optional embodiment, the molar ratio of the compound of Formula I to the amination reagent is 0.5:(0.5-0.75).

[0025] In an optional embodiment, the reaction temperature is 0-25°C and the reaction time is 1-1.5 hours.

[0026] Secondly, the present invention provides a method for preparing roxadustat, which includes the method for preparing the roxadustat intermediate as described in any of the foregoing embodiments.

[0027] The present invention has the following beneficial effects: The preparation method provided in the embodiments of the present invention avoids the use of nitro compounds, thereby avoiding the introduction of genetic impurities into the intermediates of roxadustat and roxadustat, significantly improving the safety of roxadustat. At the same time, this preparation method avoids the use of precious metals, significantly reducing the cost of preparing roxadustat. Furthermore, the preparation method is mild, has a short reaction time, and can improve the yield and purity of roxadustat intermediates. Attached Figure Description

[0028] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0029] Figure 1 The NMR spectrum of the compound provided in Example 1 of this invention. Detailed Implementation

[0030] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0031] This invention provides a method for preparing a roxadustat intermediate, which is synthesized according to the following synthetic route:

[0032] Wherein, R1 is selected from C1-C6 alkyl. Preferably, it is C1-C5 alkyl; more preferably, it is C1-C4 alkyl; even more preferably, R1 is selected from C1-C3 alkyl; for example, R1 is selected from any one of methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, isobutyl, tert-butyl, isopentyl, and isohexyl.

[0033] Specifically, the operation is as follows:

[0034] In an alkaline environment, the compound shown in Formula I is mixed with an amination reagent and reacted; specifically, in an alkaline environment, the compound shown in Formula I, a solvent, and the amination reagent are mixed and reacted.

[0035] The alkaline substance forming the alkaline environment is selected from organic or inorganic bases; preferably, it is any one of hydroxides, carbonates, bicarbonates, sodium C1-C6 alkoxides and potassium C1-C6 alkoxides; for example, including but not limited to any one of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide and sodium n-propoxide.

[0036] The amination reagent is selected from hydroxylamine reagents; more preferably, it is H2N-O-R2. Hydroxylamine phosphate, diphenylphosphonohydroxylamine, O-(trimethylsilyl)hydroxylamine, and more preferably, the amination reagent is selected from...

[0037] Wherein, R2 is selected from C1-C6 alkyl or C3-C6 cycloalkyl; R3 is selected from any one of hydroxyl, -OR4, and substituted or unsubstituted aryl; and R4 is selected from C1-C6 alkyl or C3-C6 cycloalkyl. Wherein, the C1-C6 alkyl is selected from any one of C1-C6 alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, and tert-butyl; and the C3-C6 cycloalkyl is selected from any one of C3-C6 cycloalkyl groups such as cyclopropyl, methylcyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. The substituted or unsubstituted aryl group is selected from C6-C10 aryl groups, such as phenyl and benzyl.

[0038] Furthermore, the solvent is selected from protic solvents or aprotic solvents; wherein, the protic solvent is selected from water and C1-C5 alcohol solvents, such as, but not limited to, any one of water, methanol, ethanol and propanol. The aprotic solvent is selected from furan solvents, C1-C3 chloroalkyl solvents, aromatic solvents and oxygen-substituted C3-C6 rings; such as, but not limited to, any one of toluene, tetrahydrofuran, dichloromethane and dioxane.

[0039] The molar ratio of the compound shown in Formula I to the alkaline substance is 0.5:(0.3-1.5), for example, any value between 0.5:(0.3-1.5) or any range between any two values, such as 0.5:0.3, 0.5:0.4, 0.5:0.5, 0.5:0.6, 0.5:0.7, 0.5:0.8, 0.5:0.9, 0.5:1.0, 0.5:1.1, 0.5:1.2, 0.5:1.3, 0.5:1.4, and 0.5:1.5.

[0040] The molar ratio of the compound shown in Formula I to the amination reagent is 0.5:(0.5-0.75), for example, any value between 0.5:(0.5-0.75) or any range between any two values, such as 0.5:0.5, 0.5:0.6, 0.5:0.7, and 0.5:0.75.

[0041] Furthermore, the reaction temperature is 0-25℃, for example, any value between 0℃, 5℃, 10℃, 15℃, 20℃, and 25℃, or any range between any two values. The time is 1-1.5 hours, for example, any value between 1 hour, 70 minutes, 80 minutes, and 1.5 hours, or any range between any two values.

[0042] Secondly, the present invention provides a method for preparing roxadustat, which includes the method for preparing the roxadustat intermediate as described in any of the foregoing embodiments.

[0043] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0044] Example 1

[0045] This invention provides a method for preparing methyl 2-amino-3-oxo-3-(4-phenoxyphenyl)propionate, which is synthesized according to the following synthetic route:

[0046] Specifically, under stirring, methyl 3-oxo-3-(4-phenoxyphenyl)propionate (135 g, 0.5 mol), 300 ml of water, hydroxylamine sulfonic acid (56.5 g, 0.5 mol), and sodium hydroxide (40 g, 1 mol) were added to the reaction flask. The reaction was carried out at 20°C for 60 min, and then the reaction was detected as complete. After filtration, 136 g of a pale yellow solid was obtained, with a yield of 95.4% and an HPLC purity of 99.4%. Its HPLC chromatogram is shown below. Figure 1 .

[0047] The NMR data of the product are as follows: 1H NMR (400MHz, CDCl3) δ: 8.13(m,2H),7.44(m,2H),7.26(m,1H),7.10(m,2H),7.03(m,2H),6.86(b,2H),5.17(m,1H),3.72(s,3H).

[0048] Examples 2-5

[0049] The present invention provides embodiments 2-5, the operation and method of which are the same as those of embodiment 1, only some operating conditions are different from those of embodiment 1, and the specific differences are shown in Table 1 below.

[0050] Table 1 Reaction conditions of Examples 2-5

[0051]

[0052] Example 6

[0053] This invention provides a method for preparing methyl 2-amino-3-oxo-3-(4-phenoxyphenyl)propionate, comprising:

[0054] Methyl 3-oxo-3-(4-phenoxyphenyl)propionate (135 g, 0.5 mol), toluene (300 ml), hydroxylamine sulfonic acid (56.5 g, 0.5 mol), and potassium tert-butoxide (112 g, 1 mol) were added to a reaction flask under stirring. The reaction was carried out at 0 °C, and the reaction was checked for completeness after 1.5 hours. 300 ml of water was added to the reaction solution to adjust the pH to 8-9. The mixture was separated, and the aqueous phase was extracted with 200 ml of toluene. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and crystallized to give 131 g of a pale yellow solid, with a yield of 91.9% and a purity of 99%.

[0055] Example 7

[0056] This invention provides a method for preparing methyl 2-amino-3-oxo-3-(4-phenoxyphenyl)propionate, comprising:

[0057] Methyl 3-oxo-3-(4-phenoxyphenyl)propionate (135 g, 0.5 mol), methanol (300 ml), hydroxylamine sulfonic acid (56.5 g, 0.5 mol), and sodium methoxide (54 g, 1 mol) were added to a reaction flask under stirring. The reaction was carried out at 25 °C for 60 min, after which the reaction was detected as complete. The solution was concentrated under reduced pressure, and 300 ml of water was added to adjust the pH to 8-9. 500 ml of dichloromethane was added for extraction and separation. The aqueous phase was extracted with 300 ml of dichloromethane twice. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and crystallized to give 133 g of a pale yellow solid, with a yield of 93.3% and a purity of 99.4%.

[0058] Comparative Example 1

[0059] This comparative example provides a method for preparing methyl 2-amino-3-oxo-3-(4-phenoxyphenyl)propionate, comprising:

[0060] 135 g (0.5 mol, 1.0 eq) of methyl 3-oxo-3-(4-phenoxyphenyl)propionate, 200 mL of glacial acetic acid, and 200 mL of water were added to a reaction flask. The temperature of the reaction system was lowered to 0 °C, and 52 g (0.75 mol, 1.5 eq) of sodium nitrite was added in three portions. The mixture was stirred at 0 °C for 3 hours, and the reaction proceeds were confirmed to be completely converted by TLC. 1000 mL of water and 1000 mL of dichloromethane were added to the reaction system, and the mixture was separated. The aqueous phase was extracted with 1000 mL of dichloromethane twice. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated to give 141 g of a pale yellow oily substance, methyl 2-hydroxyamino-3-oxo-3-(4-phenoxyphenyl)propionate, with a yield of 94.3%.

[0061] 120 g (0.4 mol) of methyl 2-hydroxyamino-3-oxo-3-(4-phenoxyphenyl)propionate, 1.2 g of 5% palladium on carbon, and 1200 mL of methanol were added sequentially to a reaction flask. The mixture was stirred at room temperature under a hydrogen atmosphere for 24 hours. The reaction was confirmed by HPLC. The mixture was then filtered, concentrated under reduced pressure, and the concentrate was poured into 500 mL of ethanol-hydrogen chloride solution and stirred at room temperature for 3 hours. After filtration, the solid was washed with 300 mL of cold ethanol three times. The solid was dissolved in 1000 mL of deionized water, and the pH was adjusted to 8-9 with 10% sodium hydroxide. The solid was extracted with 600 mL of dichloromethane twice, concentrated under reduced pressure, and crystallized to obtain 94 g of a pale yellow solid with an HPLC purity of ≥99% and a yield of 82%.

[0062] As can be seen, the yield of methyl 2-amino-3-oxo-3-(4-phenoxyphenyl)propionate from raw materials to product is only 77.08%, while the preparation method provided in the embodiments of the present invention can achieve a yield of over 91% for methyl 2-amino-3-oxo-3-(4-phenoxyphenyl)propionate from raw materials to product. It is evident that the yield of roxadustat intermediate is significantly improved by using the preparation method provided in the embodiments of the present invention.

[0063] Comparative Example 2

[0064] This comparative example provides a preparation method, including:

[0065] Methyl 3-oxo-3-(4-phenoxyphenyl)propionate (135 g, 0.5 mol), 300 ml of water, 85.6 g, 0.5 mol of p-toluenesulfonamide, and 40 g, 1 mol of sodium hydroxide were added to the reaction flask under stirring. The reaction was carried out at 20 °C. After 2 hours, no product was formed, and the reaction was terminated.

[0066] Comparative Example 3

[0067] This comparative example provides a preparation method, including:

[0068] Methyl 3-oxo-3-(4-phenoxyphenyl)propionate (135 g, 0.5 mol), 300 ml of water, 56.5 g, 0.5 mol of hydroxylamine sulfonic acid, and 40 g, 1 mol of sodium hydroxide were added to the reaction flask under stirring. The reaction was carried out at 45 °C. The active pharmaceutical ingredient was destroyed and no product was formed. The reaction was stopped after 30 min.

[0069] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. A method for preparing a roxadustat intermediate, characterized in that, Perform the synthesis according to the following synthesis path: R1 is selected from C1-C6 alkyl groups; Specifically, this includes: reacting a compound of formula I with an amination reagent under alkaline conditions; wherein the amination reagent is selected from H2N-O-R2, The reaction mixture consists of hydroxylamine phosphate, diphenylphosphonohydroxylamine, and O-(trimethylsilyl)hydroxylamine, wherein R2 is selected from C1-C6 alkyl or C3-C6 cycloalkyl; R3 is selected from any one of hydroxyl, benzyl, -OR4 and unsubstituted aryl; and R4 is selected from C1-C6 alkyl or C3-C6 cycloalkyl. The reaction temperature is 0-25℃.

2. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, R1 is selected from C1-C5 alkyl groups.

3. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, R1 is selected from C1-C4 alkyl groups.

4. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, R1 is selected from C1-C3 alkyl groups.

5. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, R1 is methyl or ethyl.

6. The method for preparing the roxadustat intermediate according to any one of claims 1-5, characterized in that, include: In an alkaline environment, the compound shown in Formula I, the solvent, and the amination reagent are mixed and reacted.

7. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, The alkaline substances that form the alkaline environment are selected from organic or inorganic bases.

8. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, The alkaline substance that forms the alkaline environment is any one of hydroxides, carbonates, bicarbonates, sodium C1-C6 alkoxides, and potassium C1-C6 alkoxides.

9. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, The alkaline substance that forms the alkaline environment is any one of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, and sodium n-propoxide.

10. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, R3 is selected from hydroxyl, -OR4, and C6-C10 aryl.

11. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, R3 is selected from any one of hydroxyl, -OR4, and phenyl.

12. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, The amination reagent is selected from... .

13. The method for preparing the roxadustat intermediate according to claim 6, characterized in that, The solvent is selected from protic solvents or aprotic solvents.

14. The method for preparing the roxadustat intermediate according to claim 13, characterized in that, The protic solvent is selected from water and C1-C5 alcohol solvents. The aprotic solvent is selected from furan solvents, C1-C3 chloroalkyl solvents, aromatic solvents, and dioxane.

15. The method for preparing the roxadustat intermediate according to claim 13, characterized in that, The protic solvent is selected from any one of water, methanol, ethanol, and propanol; The aprotic solvent is selected from any one of toluene, tetrahydrofuran, dichloromethane, and dioxane.

16. The method for preparing the roxadustat intermediate according to claim 9, characterized in that, The molar ratio of the compound shown in Formula I to the alkaline substance is 0.5:(0.3-1.5).

17. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, The molar ratio of the compound shown in Formula I to the amination reagent is 0.5:(0.5-0.75).

18. The method for preparing the roxadustat intermediate according to claim 1, characterized in that, The reaction time is 1-1.5 hours.

19. A method for preparing roxadustat, characterized in that, It includes the method for preparing the roxadustat intermediate as described in any one of claims 1-18.

Citation Information

Patent Citations

  • Preparation method of roxadustat intermediate

    CN111499572A